ES cell biopsy from blastocyst.
Filed under: Advanced Cell Technology, Athersys, Clinical Trials, Cytori, Embyonic Stem Cells, FDA, Geron, JNJ, Novocell, Osiris, Regenerative Medicine, adult stem cell, spinal cord injury, stem cells | Tagged: Clinical Trials, embryonic vs adult stem cell, embyryonic stem cell 2008, evolving clinical landscape, safety issues | No Comments »
Osiris Therapeutics announced that they won a DoD contract worth up to $224.7 million for developing their adult mesenchymal stem cell (MSC)-based therapeutic for treating acute radiation exposure. The contract allows for reimbursement of up to $24.7 million for continued development of their Prochymal product, and then, once the product is FDA approved for [...]
Filed under: Clinical Trials, DoD, MSCs, Osiris, Regenerative Medicine, adult stem cell, business models, stem cells | Tagged: Acute Radiation Therapy, DoD contract, Mesenchymal Stem Cell product, near term revenue, Prochymal, Type 1 diabetes | No Comments »
Osiris Therapeutics last week announced positive data that came out of their Phase I/II double blinded Chondrogen trial. They demonstrated statistically significant improvements in joint pain in patients with osteoarthritis, however this seems to be an about face compared to when they announced their “disappointing” (the CEO’s words) interim 6 [...]
Filed under: Biomaterials, Clinical Trials, Osiris, Regenerative Medicine, adult stem cell, cartilage, orthopedics, stem cells | 1 Comment »
On November 15, 2007, Athersys announced in a press release that they had received a letter from the FDA giving the green light to start a Phase I safety study of MultiStem, their adult, allogeneic stem cell product. Athersys will start an open label, dose escalation trial to test their cells after bone marrow transplantation.
This [...]
Filed under: Athersys, Clinical Trials, FDA, MSCs, Osiris, Regenerative Medicine, adult stem cell, stem cells | Tagged: adult stem cells, Athersys, business model, stem cells clinical trials | 1 Comment »
